NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT1031240227

Registered date:23/07/2024

Study on the effects of GLP1 on hepatic lipid content in AGHD complicated with obesity

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedAdult growth hormone deficiency
Date of first enrollment23/07/2024
Target sample size20
Countries of recruitment
Study typeObservational
Intervention(s)none

Outcome(s)

Primary OutcomeThe change in hepatic fat content (MRI-PDFF) from the beginning to the end of the study
Secondary Outcome1, The changes in parameters related to body composition from the beginning to the end of the study. 2, The changes in parameters related to each blood test item from the beginning to the end of the study. 3, The correlation between the change in MRI-PDFF and each parameter.

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum< 80age old
Gender
Include criteria1, Severe Adult growth hormone deficiency 2, Patients scheduled for Wegovy administration with an indication for its use, 3, BMI of 27 kg/m2 or higher with at least two obesity-related health disorders, or a BMI of 35 kg/m2 or higher 4, Receiving nutritional counseling for more than 6 months 5, Undergoing growth hormone replacement therapy
Exclude criteria1, Patients with severe trauma or undergoing surgery 2, Excessive alcohol consumers (estimated ethanol intake more than 30 g/day for men, and more than 20 g/day for women) 3, Patients with other liver diseases that cannot be ruled out, including viral hepatitis, autoimmune hepatitis, and drug-induced hepatitis 4, Patients with severe liver disfunction or liver cirrhosis classified as Child-Pugh B or C 5, Patients infected with the hepatitis virus 6, Patients with obvious malignant tumors 7, Pregnant women or women who might be pregnant 8, Patients using implanted medical devices (such as pacemakers) 9, Individuals under 20 years old or over 80 years old 10, Patients with intellectual disabilities or language problems that prevent them from fully understanding the study 11, Patients who are judged to be unable to carry out this study by the principal investigator or research assistant.

Related Information

Contact

Public contact
Name Tomomi Taguchi
Address 1-15-1, Kitazato, Mianami-ku, Sagamihara, Kanagawa Kanagawa Japan 252-0375
Telephone +81-42-778-8111
E-mail t.tomo@kitasato-u.ac.jp
Affiliation Kitasato University Hospital
Scientific contact
Name Tomomi Taguchi
Address 1-15-1, Kitazato, Mianami-ku, Sagamihara, Kanagawa Kanagawa Japan 252-0375
Telephone +81-42-778-8111
E-mail t.tomo@kitasato-u.ac.jp
Affiliation Kitasato University Hospital